GLAXO GlaxoSmithKline Pharmaceuticals Q4 FY25 results (Jan–Mar 2025) and concall
GlaxoSmithKline Pharmaceuticals reported a strong Q4 and full year FY25, with full year revenue growing 9% to INR 3723 crores and EBITDA up 30% to INR 1169 crores, driven by volume growth and margin expansion. The company successfully launched Shingrix, achieving 10,000 doses in March, and is preparing for oncology launches (Jemperli and Zejula). Despite a soft quarter for antibiotics and stunted growth in acute segments, the specialty and derms portfolios showed robust double-digit growth, supported by an enhanced digital strategy reaching over 400,000 HCPs.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 1,011 | 949 | 974 |
| EBITDA | 322 | 292 | 333 |
| Net profit | 252 | 230 | 263 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
